SUCCESSFUL APPLICATION OF PERIPHERAL VENO-ARTERIAL EXTRACORPOREAL MEMBRANE OXYGENATION FOR CARDIAC ALLOGRAFT ANTIBODY-MEDIATED REJECTION WITH SEVERE HEMODYNAMIC COMPROMISE

Introduction. Acute antibody-mediated rejection (AMR) is one of the severe complications of early and late period after heart transplantation (HT). Only few case reports and studies presented of mechanical circulatory support (MCS) application for refractory acute rejection causing hemodynamic compromise. Aim. We report the case of a woman with cardiogenic shock caused by severe AMR that was successfully treatment by peripheral venoarterial extracorporeal membrane oxygenation (VA ECMO). Material and methods. In december 2014, a 60-year-old woman with dilated cardiomyopathy was operated for HT. The patient had a good initial cardiac allograft function and no and was discharged from ICU on the 4th day after HT. 1st endomyocardial biopsy (EMB) (the 7th day after HT) showed absence of acute cellular and antibody-mediated rejection. On the 11th day after HT patient aggravated and presented clinical signs of life-threatening acute cardiac allograft dysfunction: arterial blood pressure 78/49/38 mm Hg, HR 111 in min, CVP 20 mm Hg, PAP 47/34/25 mm Hg, PCWP 25 mm Hg, CI 1.5 l/min/m2, adrenalin 110 ng/kg/min, dopamine 15 mcg/kg/min. ECG showed impairment of systolic left (LVEF 25%) and right (RVEF 15%) ventricle function, left and right ventricle diffuse hypokinesis, thickness of IVS, LV and RV wall 1.7, 1.4 and 0.8 cm, tricuspid and mitral valve regurgitation 2–3 degrees. EMB presented AMR. In conscience peripheral VA ECMO was installed. We used peripheral transcutaneous cannulation technique via femoral vessels – arterial cannula 15 F, venous cannula – 23 F, vascular catheter 14 G for anterograde leg’s perfusion. ACT 130–150 sec. AMR therapy included: methylprednisolon pulse-therapy (10 mg/kg for 5 day), IgG, plasmapheresis (No 7), rituximab. Results. Under MCS by VA ECMO we noted quick improvement of hemodynamic, metabolic homeostasis and organ functions. On the 6th day of VA ECMO (blood flow 1.8 l/min): arterial blood pressure 133/81/54 mm Hg, CVP 5 mm Hg, PAP 31/21/12 mm Hg, PCWP 12 mm Hg, CI 3,4 l/min/м2, HR 85 in min, LVEF 53%, IVS 1.3 cm, mitral valve regurgitation <1 degree, inotropic support was discontinued. Control EMB showed resolution of AMR. Duration of VA ECMO was 7 days. Patient was discharged from ICU on the 2nd and 26th day after VA ECMO in stable clinical status. Conclusion. VA ECMO should be crucial component of treatment of cardiac allogaft antibody-mediated rejection with severe hemodynamic compromise. 

1. Белецкая ЛВ, Куприянова АГ. Антителоопосредованное (гуморальное) отторжение аллотрансплантата сердца в клинике: Очерки клинической трансплантологии / Под ред. СВ. Готье. М.–Тверь: Триада, 2009: 285–325. Beletskaya LV, Kupriyanova AG. Antitelooposredovannoe (gumoralnoe) ottorzhenie allotransplantata serdtsa v klinike: Ocherki klinicheskoy transplantologii / Pod red. SV Gotie. M.–Tver: Triada, 2009: 285–325.

2. Шумаков ВИ, Хубутия МШ, Белецкая ЛВ. Отторжение гуморального типа при аллотрансплантации сердца. Тверь: Триада, 2003. Shumakov VI, Hubutiya MSh, Beletskaya LV. Ottorzhenie gumoralnogo tipa pri allotransplantatsii serdtsa. Tver: Triada, 2003.

3. Hsu CY., Chi NH, Chou NK, Shun CT, Chen YS, Huang SC et al. Antibody-mediated rejection after orthotopic heart transplantation: a 9-year single-institution experience. Transplant. Proc. 2014; 46 (3): 925–928.

4. Hammond EH, Yowell RL, Nunoda S, Menlove RL, Renlund DG, Bristow MR et al. Vascular (humoral) rejection in heart transplantation: pathologic observations and clinical implications. J. Heart. Transplant. 1989; 8: 430–443.

5. Michaels PJ., Espejo ML, Kobashigawa J, Alejos JC., Burch C, Takemoto S et al. Humoral rejection in cardiac transplantation: risk factors, hemodynamic consequences and relationship to transplant coronary artery disease. J. Heart. Lung Transplant. 2003; 22: 58–69.

6. Caceres M, Czer LSC, Esmailian F, Luthringer D, Ramzy D, Moriguchi J. Staged approach to mechanical circulatory support. Tex. Heart. Inst. J. 2013; 40: 596– 599.

7. Готье СВ, Попцов ВН, Спирина ЕА. Экстракорпоральная мембранная оксигенация в кардиохирургии и трансплантологии. М.–Тверь: Триада, 2013: 116–123; 138–160. Gotie SV, Poptsov VN, Spirina EA. Ekstrakorporalnaya membrannaya oksigenatsiya v kardiohirurgii i transplantologii. M.–Tver': Triada, 2013: 116–123; 138–160.

8. Попцов ВН, Спирина ЕА, Саитгареев РШ, Шумаков ДВ, Захаревич ВМ, Слободяник ВВ и др. Периферическая вено-артериальная мембранная оксигенация как метод механической поддержки кровообращения перед трансплантацией сердца. Вестник трансплантологии и искусственных органов. 2013; 15 (2): 23–35. Poptsov VN, Spirina EA, Saitgareev RSh, Shumakov DV, Zaharevich VM, Slobodyanik VV et al. Perifericheskaya veno-arterialnaya membrannaya oksigenatsiya kak metod mehanicheskoy podderzhki krovoobrascheniya pered transplantatsiey serdtsa. Vestnik transplantologii i iskusstvennyh organov. 2013; 15 (2): 23–35.

9. Morales DL, Braud BE, Price JF, Dreyer WJ, Denfield SW, Clunie SK. Use of mechanical circulatory support in pediatric patients with acute cardiac graft rejection. ASAIO J. 2007; 53: 701–705.

10. Lund LH, Edwards LB, Kucheryavaya AY, Dipchand AI еt al. The Registry of the International Society for Heart and Lung Transplantation: Thirtienth Official Adult Heart Transplant Report – 2013. J. Heart. Lung. Transplant. 2013; 32: 951–965.

11. Mills RM, Naftel DC, Kirklin JK, Van Bakel AB, Jaski BE, Massin EK et al. Heart transplant rejection with hemodynamic compromise: a multiinstitutional study of the role endomyocardial cellular infiltrate. J. Heart. Lung. Transplant. 1997; 16: 813–821.

12. Chin C. Cardiac antibody-mediated rejection. Pediatr Transplant. 2012; 16: 404–412.

13. Reed EF, Demetries AJ, Hammond E, Itescu S et al. Acute antibody-mediated rejection of cardiac transplants. J. Heart. Lung Transplant. 2006; 25: 153–159.

14. Keren A, Hayes HM, O’driscoll G. late humoral rejection in a cardiac transplant recipient treated with the anti-CD 20 monoclonal antibody rituximab. Transplant. Proceeding. 2006; 38: 1520–1522.

15. Kobashigawa J, Crespo-Leiro MG, Ensminger SM et al. Report from a consensus conference on antibody-mediated rejection in heart transplantation. J. Heart. Lung Transplant. 2011; 30: 252–269.

16. Berry GJ, Burke MM, Andersen C et al. The 2013 ISHLT Working Formulation for the standardization of nomenclature in the pathologic diagnosis of antibody-mediated rejection in heart transplantation. J. Heart. Lung Transplant. 2013; 32: 1147–1162.

17. Saito S, Matsumiya G, Fukushima N, Sakaguchi T, Fujita T, Ueno T et al. Successful treatment of cardiogenic shock caused by humoral cardiac allograft rejection. Circ. J. 2009; 73: 970–973.

18. Almuti K, Haythe J, Dwyes E, Itescu S, Burke E, Green P et al. The changing pattern of humoral rejection in cardiac transplant recipients. Transplantation. 2007; 84: 498–503.

19. Fishbein MC, Kobashigawa J. Biopsy-negative cardiac transplant rejection: etiology, diagnosis and therapy. Curr. Opin. Cardiol. 2004; 19: 166–169.

20. Joyce D, Southard R, Torre-Amione G, Noon G, Land G, Loebe M. Impact of left ventricular assist device (LVAD)-mediated humoral sensitization on post-transplant outcomes. J. Heart. Lung Transplant. 2005; 24: 2054–2059.

21. Baran D, Gass A, Galin I еt al. Lack of sensitization and equivalent post-transplant outcomes with the Novacor left ventricular assist device. J. Heart. Lung Transplant. 2005; 24: 1886–1890.

22. Colvin R, Smith R. Antibody-mediated organ-allograft rejection. Nat. Rev. Immunol. 2005; 10: 807–817.

23. Liets K, John R, Kocher A et al. Incresead prevalence of autoimmune phenomena and greater risk for alloreactivity in female heart transplant recipients. Circulation. 2001; 104 (1): I177–I183.

24. Brunner-La Rocca HP, Schneider J, Kunzli A, Turina M, Kiowski W. Cardiac allograft rejection late after transplantation is a risk factor for graft coronary artery disease. Transplantation. 1998; 65: 538–543.

25. Taylor DO, Yowell RL, kfoury AG, Hammond EH, Renlund DG. Allograft coronary artery disease clinical correlations with circulating anti-HLA antibodies and the immunohistopathologic pattern of vascular rejection. J. Heart. Lung Transplant. 2000; 19: 518–552.

26. Tambur AR, Pamboukian SV, Constanzo MR et al. The presence of HLA-directed antibodies after heart transplantation is associated with poor allograft outcome. Transplantation. 2005; 80: 1019–1025.

27. Grauhan O, Knosalla C, Ewert R et al. Plasmapheresis and cyclophosphamide in the treatment of humoral rejection after heart transplantation. J. Heart. Lung Transplant. 2001; 20: 316–321.

28. Kaczmarek I, Deutsh MA, Sadoni S et al. Successful management of antibody-mediated cardiac allograft rejection with combined immunoadsorption and antiCD20 monoclonal antibody treatment: case report and literature review. J. Heart. Lung Transplant. 2007; 26: 511–517.

29. Arafa O, Fiane AE, Svennevig JL, Geiran OR. Mechanical circulatory support of heart transplant patients. Transplant. Proc. 2001; 33: 1603–1604.

30. Costello JM, Pahl E. Prevention and treatment of severe hemodynamic compromise in pediatric heart transplant patients. Paediatr. Drugs. 2002; 4: 705–715.

31. Buja LM. Acute pump failure of the transplanted heart. Texas Heart. Institute J. 2013; 40: 600–601.

32. Kar B, Sukhdeep SB, Shan NR, Loylka P. Percutaneous circulatory support in cardiogenic shock. Circulation. 2012; 125: 1809–1817.

33. Valez-Martinez M, Rao K, Warner J et al. Successful use of the TandemHeart Ventricular Assist Device as a bridge to recovery for acute cellular rejection in cardiac transplant patient. Transplant. Proceeding. 2011; 43: 3882–3884.

34. Santise G, Panarello G, Ruperto C et al. Extracorporeal membrane oxygenation for graft failure after heart transplantation: a multidisciplinary approach to maximize weaning rate. Int. J. Artif. Organs. 2014; 37: 706–714.

35. Yang F, Jia ZS, Xing JL et al. Effects of intra-aortic balloon pump on cerebral blood flow during peripheral venoarterial extracorporeal membrane oxygenation support. J. Transl. Med. 2014; 12: 106. doi: 10.1186/14795876-12-106.

36. Cheng JM, Den Uil CA, Hoeks SE et al. Percutaneous left ventricular assist devices vs. intra-aortic balloon pump counterpulsation for treatment of cardiogenic shock: a meta-analysis of controlled trials. Eur. Heart. J. 2009; 30: 2102–2108.

37. Beyer AT, Hui PY, Hauesslein E. The Impella 2.5 l for percutaneous mechanical circulatory support in severe humoral allograft rejection. J. Invasiv. Cardiol. 2010; 22: E37–39.

38. Samoukovic G, Al-Atassi T, Rosu C, Giannetti N, Cecere R. Successful treatment of heart failure due to acute transplant rejection with the Impella LP 5.0. Ann. Thorac. Surg. 2009; 88: 271–273.

39. Kavarana MN, Sinha P, Naka Y, Oz MC, Edwards NM. Mechanical support for the failing cardiac allograft: a single-center experience. J. Heart. Lung Transplant. 2003; 22: 542–547.

40. Rajagopal V, Steahr G, Wilmer CI, Raval NY. A novel percutaneous mechanical biventricular bridge to recovery in severe cardiac allograft rejection. J. Heart. Lung Transplant. 2010; 29: 93–95.